Bitcoin hoarding giant Strategy clung to its place in the Nasdaq 100 on Friday, continuing its year-long stint in the ...
Lululemon Athletica (LULU) to exit the Nasdaq 100 as part of the gauge's annual shakeup, with Seagate (STX) and five others ...
Biogen (BIIB) stock slips as HSBC downgrades to a Sell equivalent rating as part of an analysis that included an upgrade on ...
Biogen's fair value estimate has nudged higher to about $178.76 per share, even as its discount rate ticks up slightly to roughly 7.49 %, signaling a modestly higher perceived risk backdrop. The shift ...
If you have been wondering whether Biogen's recent share price makes it a bargain or a value trap, you are not alone. This article is designed to help you cut through the noise and focus on what the ...
Analysts at Jefferies see blockbuster potential in zorevunersen in Dravet syndrome, with sales potentially reaching $1 ...
Cryptopolitan on MSN
Bitcoin’s Strategy remains in Nasdaq 100 despite mountain of criticism over fund‑like profile
Bitcoin giant Strategy kept its spot in the Nasdaq 100 on Friday, holding its year-long run inside the index while debate ...
Pharmaceutical Technology on MSN
Health Canada approves Biogen’s Zurzuvae for PPD treatment
Biogen has received an NOC from Health Canada for Zurzuvae, a NAS, as a treatment for moderate or severe PPD in women.
Health Canada has approved zuranolone, sold under the brand name Zurzuvae, as the first oral treatment for moderate to severe ...
24/7 Wall St. on MSN
Here Are Wednesday’s Top Wall Street Analyst Research Calls: AbbVie, Amazon.com, Biogen, EchoStar, Ferrari, GE Vernova, PepsiCo, Take-Two Interactive, and More
Futures are trading modestly lower as the big day has finally arrived: the Federal Reserve will wrap up its last meeting of ...
Long-term Phase 1/2a and open label extension (OLE) data for zorevunersen on top of standard of care anti-seizure medicines ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback